Journal of Research in Pharmacy Practice最新文献

{"title":"Association Between Atorvastatin Exposure and Low Folate Status: A Case-Control Study.","authors":"Roberto Lozano,&nbsp;Irati Apesteguía,&nbsp;Alejandro Martínez","doi":"10.4103/jrpp.jrpp_66_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_66_22","url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study is to assess the association between exposure to atorvastatin (ATV) and low-plasma folate (PF) status.</p><p><strong>Methods: </strong>The sample consisted of patients admitted to the internal medicine service of a basic general hospital, located in Zaragoza (Spain). We adopted a pharmacoepidemiological case-control study design. For this, the number of treatment days (TDs) of all the drugs part of their treatment during the study period was obtained from each patient in the sample. The cases were comprised by the number of patient's TDs for which PF ≤3 mg/dl and the controls by the number of patient's TDs for which PF >3 mg/dl. To measure the strength of the association, the odds ratios (ORs) were calculated. The Chi-square test, using the Bonferroni correction, was used to calculate the statistical significance.</p><p><strong>Findings: </strong>The sample consisted of 640 polymedicated patients. The mean PF obtained were 8.0 ± 4.6 mg/dl and 2.1 ± 0.6 mg/dl, for the cases and controls, respectively; the total number of TDs for the cases and controls were 7615 and 57899, respectively. We obtained a U-shaped curve when representing the dose of ATV against the corresponding ORs when comparing cases with control.</p><p><strong>Conclusion: </strong>Exposure to ATV at 10 or 80 mg is associated with an augmented risk of low folate status. We recommend implementing guidelines for mandatory folic acid fortification in patients exposed to ATV doses of 10 or 80 mg.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 3","pages":"124-126"},"PeriodicalIF":1.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/9d/JRPP-11-124.PMC10252577.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9623251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Benefits of Selenium Supplementation in Patients with Kidney Disease.","authors":"Shirinsadat Badri,&nbsp;Sahar Vahdat,&nbsp;Morteza Pourfarzam,&nbsp;Samaneh Assarzadeh,&nbsp;Shiva Seirafian,&nbsp;Sara Ataei","doi":"10.4103/jrpp.jrpp_3_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_3_22","url":null,"abstract":"<p><p>Trace element deficiency is common among patients with end-stage renal disease (ESRD); the reason is that since these patients undergo dialysis, they lose these elements more than healthy people, and also the use of trace elements is restricted due to loss of appetite. Selenium (Se) is a trace element that is essential for the oxidative stress defense system. Se deficiency leads to some complications similar to those often seen in ESRD patients, such as all-cause mortality due to cardiovascular diseases, bone loss, uric acid elevation, and anemia. This article aims to review the evidence on consequences of Se deficiency in ESRD patients, as well as effects of Se supplementation in hemodialysis patients. Multiple databases were searched to summarize the available evidence on selenium's role in kidney diseases. Since the complications of ESRD and those of Se deficiency are mostly similar, this triggers the idea that Se deficiency may be considered as a cause of these problems, but it needs to be more assessed that Se deficiency is a single factor or there are other factors participated in. Also the role of Se supplementation on resolving the mentioned complications, needs to be more studied through welldesigned clinical studies.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"149-158"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/5f/JRPP-10-149.PMC9235365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Effectiveness of N-Acetylcysteine in the Prevention of Colistin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial.","authors":"Sedigheh Mosayebi,&nbsp;Rasool Soltani,&nbsp;Fatemeh Shafiee,&nbsp;Samane Assarzadeh,&nbsp;Atousa Hakamifard","doi":"10.4103/jrpp.jrpp_90_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_90_21","url":null,"abstract":"<p><strong>Objective: </strong>The present study aimed to evaluate the effectiveness of N-Acetylcysteine (NAC), as an antioxidant, in preventing nephrotoxicity in patients receiving colistin.</p><p><strong>Methods: </strong>In a randomized controlled clinical trial, eligible participants receiving colistin were divided into two groups including drug (<i>n</i> = 43) and control (<i>n</i> = 39). In the drug group, 1200 mg of NAC was administered daily for 10 days concurrently with colistin. Patients in the control group received only colistin. The serum creatinine level (SCr), blood urea nitrogen (BUN), and creatinine clearance (CrCl) at baseline and every other day, and the number of cases with acute kidney injury (AKI) during the study were recorded. Before starting treatment and on day 5, the level of urinary neutrophil gelatinase-associated lipocalin (NGAL) was determined. Finally, the values were compared between the groups.</p><p><strong>Findings: </strong>There was a significant increase in SCr and BUN and a significant reduction in CrCl in both groups, but there was not any significant difference between the two groups at any time. Changes in the urine NGAL levels were not significantly different between the two groups. Even though the number of cases with AKI in the drug group (8 cases, 18.6%) was less than the control group (11 cases, 28.2%), the difference was not statistically significant (<i>P</i> = 0.303).</p><p><strong>Conclusion: </strong>Simultaneous administration of NAC with a dose of 1200 mg daily does not have any effect in the prevention of colistin-induced nephrotoxicity.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"159-165"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/33/df/JRPP-10-159.PMC9235367.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40409998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Evaluation between the LaxaPlus Barij^® and Polyethylene Glycol (4000) in the Pediatric Functional Constipation in Children 2-15 Years Old.","authors":"Peiman Nasri,&nbsp;Shima Saeidi,&nbsp;Hosein Saneian,&nbsp;Fatemeh Famouri,&nbsp;Somayeh Sadeghi,&nbsp;Leila Mohammad Taghizadeh Kashani,&nbsp;Majid Khademian","doi":"10.4103/jrpp.jrpp_57_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_57_21","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the LaxaPlus Barij^® and polyethylene glycol (4000) in pediatric (children 2-15 years old) functional constipation.</p><p><strong>Methods: </strong>The present study is a randomized clinical trial. The study population included patients with functional constipation aged 2-15 years who were referred to the gastrointestinal clinic of Imam Hossein hospital in Isfahan in 2019. Patients were randomly assigned into two treatment groups. Data analysis was performed using SPSS software. The significance level in the present study is considered <0.05.</p><p><strong>Findings: </strong>Sixty children with functional constipation were selected based on the inclusion and exclusion criteria in this study. The present study results showed no significant difference between demographic characteristics, including age, weight, and gender of children with constipation in the two groups (<i>P</i> > 0.05). The present study results showed that both groups' mean stool consistency and the number of bowel movements increased significantly after the intervention (<i>P</i> < 0.05). However, the number of bowel movements in the first group was significantly higher than in the second group (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The present study results showed that both drugs effectively treat children with functional constipation. However, after 8 weeks of intervention, the frequency of bowel movements, pain intensity, and abdominal pain in the group LaxaPlus Barij^® was more effective. However, the level of satisfaction did not differ significantly between the two groups.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"180-184"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5f/cd/JRPP-10-180.PMC9235366.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40409997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-Care Professionals' Knowledge and Practice Regarding Disposal of Medicines in Primary Health-Care Facilities in South Africa: Impact and Implications.","authors":"Kesentseng Jackson Mahlaba,&nbsp;Elvera Anna Helberg,&nbsp;Brian Godman,&nbsp;Amanj Kurdi,&nbsp;Johanna Catharina Meyer","doi":"10.4103/jrpp.jrpp_84_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_84_21","url":null,"abstract":"<p><strong>Objective: </strong>Professional nurses, pharmacists, and medical practitioners are responsible for disposing of medicines within health-care facilities. South African regulations stipulate that medicines should not be disposed of through sewage systems because of the potential impact on patients and the environment. Consequently, our objective was to determine knowledge and practices among health-care professionals (HCPs) in South Africa and the information they provide to patients regarding the safe disposal of unused/expired/damaged medicines to provide future guidance with identified concerns.</p><p><strong>Methods: </strong>A descriptive study was conducted among 165 HCPs at 16 primary health-care clinics in two subdistricts of the city of Tshwane in Gauteng Province through self-administered questionnaires.</p><p><strong>Findings: </strong>Only 23.5% of HCPs stated that they participated in destroying medicines within their facilities. More than half (65.1%) also reported that they always counsel patients regarding the safe storage of their medicines in their homes, with 27.9% indicating they counsel patients on the safe disposal of their medicines during consultations. More than half (65.1%) also reported that patients never asked about the disposal of medicines. Of concern is that incineration (31.9%), flushing down the toilet (20.6%), and flushing down the sink (9.9%) were regarded by HCPs as correct disposal methods, while 9.6% stated that they did not know the correct methods. In addition, 71.1% reported never receiving training regarding the safe disposal of medicine.</p><p><strong>Conclusion: </strong>There is an urgent need to educate HCPs regarding appropriate medicine waste disposal in South Africa. This can start with including this topic in the curriculum of HCPs, including pharmacists, and continuing post qualification.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"185-190"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/6e/JRPP-10-185.PMC9235368.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient Satisfaction with Pharmaceutical Services in Makkah: A Cross-sectional Study.","authors":"Abdulaziz Salamatullah,&nbsp;Majid Ali,&nbsp;Alhanouf Alharbi,&nbsp;Alhanoof Balhmer,&nbsp;Raneem Jalal,&nbsp;Dina Alabdali,&nbsp;Ghufran Alhajjaji","doi":"10.4103/jrpp.jrpp_94_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_94_21","url":null,"abstract":"<p><strong>Objective: </strong>Patient satisfaction is considered an essential indicator of the treatment outcomes of pharmaceutical services. This study aimed to assess patient satisfaction with the pharmaceutical services at the Ministry of Health (MOH) hospitals in Makkah city in Saudi Arabia.</p><p><strong>Methods: </strong>A cross-sectional study was conducted via an interview-based questionnaire that involved patients who visited the outpatient pharmacy in five MOH hospitals from August 2018 to September 2018. The data were collected using a previously published, validated, and reliable questionnaire. The questionnaire was translated and piloted for the local context.</p><p><strong>Findings: </strong>Data of 295 respondents were analyzed. The overall mean score of satisfaction level with the pharmaceutical services was found to be 2.50 out of a maximum score of 3. The item that the patients were most satisfied with was, \"The extent of cleanliness in the waiting area for the provision of pharmaceutical services\" (mean = 2.80) whereas the item the patients were least satisfied with was, \"The information the pharmacist gives you about the proper storage of your medication\" (mean = 2.00). \"Illiterate\" patients and those who visited the pharmacy first time had significantly higher satisfaction levels compared to those with other educational categories and those who had visited the pharmacy before, respectively.</p><p><strong>Conclusion: </strong>Our study showed that the overall level of satisfaction of patients with pharmaceutical services was high.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"174-179"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/c8/JRPP-10-174.PMC9235369.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40406029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Outcomes of Aluminum Phosphide Poisoning in Khorshid Referral Hospital, Isfahan, Iran: A Retrospective Study.","authors":"Gholamali Dorooshi,&nbsp;Meysam Mirzae,&nbsp;Negah Tavakoli Fard,&nbsp;Shafeajafar Zoofaghari,&nbsp;Nastaran Eizadi Mood","doi":"10.4103/jrpp.jrpp_88_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_88_21","url":null,"abstract":"<p><strong>Objective: </strong>Aluminum phosphide (ALP) (rice-tablet) is a common cause of adult poisoning in Iran, including Isfahan. So far, no effective treatment has been identified for this poisoning. We aimed to investigate the outcome of ALP poisoned patients admitted to the clinical toxicology ward of Khorshid Hospital in Isfahan from 2017 to 2019.</p><p><strong>Methods: </strong>This chart-review study was performed on the population of ALP poisoned patients admitted to the clinical toxicology ward of Khorshid University Hospital from 2017 to 2019 treated with the hospital's new treatment protocol, using the complete enumeration approach. The outcomes were determined by reviewing and abstracting medical charts of ALP poisoned patients from the hospital archive.</p><p><strong>Findings: </strong>The most common complaints at admission were depressed consciousness (41.9%) and vomiting (32.2%). There was no significant change in blood sugar, pH, base excess (BE), and venous blood bicarbonate throughout their hospitalization (<i>P</i> > 0.05). Treatment outcomes had a significant relationship with blood pH 2 h and 6 h after admission and the BE 6 h after admission (<i>P</i> < 0.05). There was also a significant relationship between the outcome and the length of stay, initial ejection fraction (EF), and EF in predischarge echocardiography (<i>P</i> < 0.05). Out of 31 patients, 24 (77.4%) died within 72 h, 5 (16.1%) recovered without any complication, and 2 (6.5%) recovered with some complications.</p><p><strong>Conclusion: </strong>The mortality rate of ALP poisoned patients was reasonably high and can be attributed to the poor efficacy of the new treatment protocol or the long time it takes for patients to reach the hospital and start receiving treatments.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"10 4","pages":"166-173"},"PeriodicalIF":1.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/eb/ef/JRPP-10-166.PMC9235370.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40410000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-dose Intravenous Vitamin C in Early Stages of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Double-blind, Randomized, Controlled Clinical Trial.","authors":"Zohre Labbani-Motlagh,&nbsp;Shahideh Amini,&nbsp;Rasoul Aliannejad,&nbsp;Anahita Sadeghi,&nbsp;Gita Shafiee,&nbsp;Ramin Heshmat,&nbsp;Mohamadreza Jafary,&nbsp;Mona Talaschian,&nbsp;Maryam Akhtari,&nbsp;Ahmadreza Jamshidi,&nbsp;Mahdi Mahmoudi,&nbsp;Kourosh Sadeghi","doi":"10.4103/jrpp.jrpp_30_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_30_22","url":null,"abstract":"<p><strong>Objective: </strong>Based on previous studies in the sepsis population, Vitamin C could prevent injuries when administered in high doses and before the damage is established. This study aimed to evaluate the protective potentials of high-dose Vitamin C in the progression of coronavirus disease 2019 (COVID-19).</p><p><strong>Methods: </strong>A double-blind, placebo-controlled clinical trial was conducted. Patients with moderate-to-severe disease severity based on the World Health Organization definition were enrolled and received 12 g/d Vitamin C (high-dose intravenous Vitamin C [HDIVC]) or placebo for 4 days. Sequential Organ Failure Assessment (SOFA) score as a primary outcome, National Early Warning Score, Ordinal Scale of Clinical Improvement, and cytokine storm biomarkers were recorded on days 0, 3, and 5. Survival was also assessed on day 28 after enrollment.</p><p><strong>Findings: </strong>Seventy-four patients (37 patients in each group) were enrolled from April 5, 2020, to November 19, 2020, and all patients completed follow-up. A lower increase in SOFA score during the first 3 days of treatment (+0.026 vs. +0.204) and a higher decrease in this parameter in the last 2 days (-0.462 vs. -0.036) were observed in the treatment group. However, these differences did not reach a significance level (<i>P</i> = 0.57 and 0.12, respectively). Other indices of clinical and biological improvement, length of hospitalization, and intensive care unit admission days were the same between the two groups. Treatment did not affect the 28-day mortality.</p><p><strong>Conclusion: </strong>Among patients with moderate-to-severe disease of COVID-19, the use of HDIVC plus standard care resulted in no significant difference in SOFA score or 28-day mortality compared to the standard care alone.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 2","pages":"64-72"},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/33/JRPP-11-64.PMC9926917.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10741987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Clinical Manifestations of Patients Poisoned with Tricyclic Antidepressants Alone or with Benzodiazepine Intoxication According to the Dose of Benzodiazepines.","authors":"Gholamali Dorooshi,&nbsp;Rasool Kermani,&nbsp;Ali Mohammad Sabzghabaee,&nbsp;Marjan Mansourian,&nbsp;Nastaran Eizadi-Mood","doi":"10.4103/jrpp.jrpp_43_21","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_43_21","url":null,"abstract":"<p><strong>Objective: </strong>Tricyclic antidepressants poisoning (TCA) is associated with cardiovascular complications, electrocardiographic abnormalities, and central nervous system toxicity. This study aimed to compare the clinical manifestations of poisoned patients with tricyclic antidepressants alone or with benzodiazepine (BZD) intoxication according to the dose of BZDs.</p><p><strong>Methods: </strong>In this case-control study, 120 patients with TCA poisoning were divided into four groups: the first group of TCA poisoning alone, the second group of TCA and BZD poisoning of <7.75 mg, the third group of TCA and B poisoning of 7.75 to 80 mg, and the fourth group of more than 80 mg of TCA and BZD poisoning. Patients' demographic, clinical, and cardiac information was extracted from their records at admission and 6 h after admission.</p><p><strong>Findings: </strong>Cardiac complications 6 h after referral and total cardiac complications between TCA and TCA low-dose BZD groups were significantly reduced in the low-dose BZD poisoning group. Comparison of TCA and TCA groups with a moderate dose of BZD showed a significant reduction in time six and total cardiac complications. However, due to the significant difference in TCA values between the two groups, the results are not significant. Comparing the two groups of TCA and TCA with a high dose of BZD, both 6-hour cardiac complications and total cardiac complications in the high-dose BZD group, it was significantly reduced. However, the loss of consciousness was also considerably greater in the high-dose BZD group than in the TCA group.</p><p><strong>Conclusion: </strong>Concomitant BZDs with TCA can reduce cardiovascular complications from TCA poisoning. However, with high doses of BZDs, there is a greater loss of consciousness.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 2","pages":"59-63"},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/5c/JRPP-11-59.PMC9926914.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10741984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe Ondansetron-associated Hypokalemia in a Patient Diagnosed with Aspiration Pneumonia.","authors":"Atousa Hakamifard,&nbsp;Amir Aria,&nbsp;Mahnaz Momenzadeh","doi":"10.4103/jrpp.jrpp_13_22","DOIUrl":"https://doi.org/10.4103/jrpp.jrpp_13_22","url":null,"abstract":"<p><p>This case report aims to introduce a patient with severe hypokalemia as one of the rare complications of ondansetron injection. The stroke patient was 56 years old and hospitalized in the emergency department with and purulent sputum. The symptoms and lung computed tomography scan confirmed the diagnosis of aspiration pneumonia. A nasogastric tube was inserted, and food gavage was performed for the patient. The treatment was started with meropenem to manage aspiration pneumonia. The patient could not tolerate the gavage. Consequently, ondansetron was prescribed, but severe hypokalemia of 2.5 mEq/l was developed. The causes of hypokalemia were evaluated. The hematological, biochemical, and liver function tests were done, and the potassium level was measured daily. Afterward, causes of hypokalemia was ruled out and with discontinuation of ondansetron the hypokalemia was resolved. Hypokalemia may be caused by ondansetron. It is required that potassium monitoring be always considered during administrating of this medicine.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":"11 2","pages":"87-90"},"PeriodicalIF":1.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/7e/JRPP-11-87.PMC9926912.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10741985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}